Cleara Biotech B.V.

Cleara Biotech B.V. is a biopharmaceutical R&D company founded in 2018 and based in The Netherlands. The company's focus is on targeting cellular senescence to extend human healthspan at old age and to counteract late stage cancer. Cleara is dedicated to the discovery and development of therapies against cancer and chronic diseases through the selective elimination of subtypes of cellular senescence. Their approach involves a detailed understanding of the molecular and biological pathways underlying these pathological phenotypes. Cleara has developed a disruptive and proprietary platform technology to design and optimize (peptide-based) therapeutics that exploit the weak spots of senescent cells for safe and selective clearance. The company's lead FOXO4 program is specifically focused on the treatment of metastatic, mutant-p53 cancer by targeting "scarred" cellular senescence. Cleara acknowledges the presence of different types of senescence and does not pursue a one-size-fits-all approach. Instead, they aim to develop specific and safe compounds against unique subtypes, with the goal of progressing these into clinical development for precision medicine against specific diseases. Cleara's innovative approach has attracted Convertible Note investment from FJ Labs in February 20, 2024. The company's commitment to developing targeted therapies against specific subtypes of senescence with associated biomarkers represents a promising opportunity in the biotechnology industry. With its unique focus and promising technology, Cleara Biotech B.V. presents an intriguing investment prospect for venture capital.